PL2632468T3 - Kompozycje terapeutyczne do leczenia symetrycznej polineuropatii cukrzycowej - Google Patents

Kompozycje terapeutyczne do leczenia symetrycznej polineuropatii cukrzycowej

Info

Publication number
PL2632468T3
PL2632468T3 PL11835385T PL11835385T PL2632468T3 PL 2632468 T3 PL2632468 T3 PL 2632468T3 PL 11835385 T PL11835385 T PL 11835385T PL 11835385 T PL11835385 T PL 11835385T PL 2632468 T3 PL2632468 T3 PL 2632468T3
Authority
PL
Poland
Prior art keywords
therapeutic compositions
symmetrical polyneuropathy
diabetic
diabetic symmetrical
polyneuropathy
Prior art date
Application number
PL11835385T
Other languages
English (en)
Inventor
Paul Fernyhough
Nigel A. Calcutt
Lakshmi Kotra
Original Assignee
University Of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Manitoba filed Critical University Of Manitoba
Publication of PL2632468T3 publication Critical patent/PL2632468T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL11835385T 2010-10-25 2011-10-24 Kompozycje terapeutyczne do leczenia symetrycznej polineuropatii cukrzycowej PL2632468T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40650210P 2010-10-25 2010-10-25
US201161531803P 2011-09-07 2011-09-07
EP11835385.3A EP2632468B1 (en) 2010-10-25 2011-10-24 Therapeutic compositions for diabetic symmetrical polyneuropathy
PCT/CA2011/001186 WO2012055018A1 (en) 2010-10-25 2011-10-24 Therapeutic compositions for diabetic symmetrical polyneuropathy

Publications (1)

Publication Number Publication Date
PL2632468T3 true PL2632468T3 (pl) 2018-04-30

Family

ID=45993001

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11835385T PL2632468T3 (pl) 2010-10-25 2011-10-24 Kompozycje terapeutyczne do leczenia symetrycznej polineuropatii cukrzycowej
PL17206278.8T PL3363439T3 (pl) 2010-10-25 2011-10-24 Kompozycje terapeutyczne do leczenia cukrzycowej polineuropatii symetrycznej

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17206278.8T PL3363439T3 (pl) 2010-10-25 2011-10-24 Kompozycje terapeutyczne do leczenia cukrzycowej polineuropatii symetrycznej

Country Status (13)

Country Link
US (3) US10307428B2 (pl)
EP (3) EP3363439B1 (pl)
CN (1) CN103298473B (pl)
CA (1) CA2804797C (pl)
DK (1) DK2632468T3 (pl)
ES (2) ES2655688T3 (pl)
HR (1) HRP20250395T1 (pl)
HU (1) HUE070784T2 (pl)
NO (1) NO2632468T3 (pl)
PL (2) PL2632468T3 (pl)
PT (1) PT2632468T (pl)
RS (1) RS66691B1 (pl)
WO (1) WO2012055018A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3082845T3 (pl) * 2013-12-20 2021-08-02 University Of Manitoba Sposoby i kompozycje do leczenia neuropatii obwodowych
US9743513B2 (en) 2014-12-26 2017-08-22 Industrial Technology Research Institute Flexible electronic device
KR20220003519A (ko) * 2019-03-26 2022-01-10 윈산토르, 아이엔씨. 말초 신경병증 치료를 위한 국소 제형
US20240316028A1 (en) * 2023-03-16 2024-09-26 Glaukos Corporation Ophthalmic cream formulations and their uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
AU753270B2 (en) * 1998-05-21 2002-10-10 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
CN1509172A (zh) * 2001-05-25 2004-06-30 ά����ҩ��˾ 哌仑西平眼用凝胶剂
CA2461696A1 (en) * 2001-09-26 2003-04-03 Alison B. Lukacsko Compositions and methods for inhibiting eccrine perspiration in humans
US20090325975A1 (en) * 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
WO2007061739A2 (en) * 2005-11-21 2007-05-31 Schering-Plough Ltd. Pharmaceutical compositions comprising buprenorphine
CN101472476B (zh) * 2006-06-16 2013-10-30 泰拉科斯有限公司 毒蕈碱型受体m1拮抗剂在制备治疗肥胖症的药物中的应用
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US20080255062A1 (en) * 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
CN101422610A (zh) * 2007-12-04 2009-05-06 袁才蔚 一种化学药复合物制剂及其应用

Also Published As

Publication number Publication date
CN103298473A (zh) 2013-09-11
EP4537829A3 (en) 2025-06-18
ES2655688T3 (es) 2018-02-21
US20190046540A1 (en) 2019-02-14
US11925649B2 (en) 2024-03-12
HRP20250395T1 (hr) 2025-05-23
CA2804797A1 (en) 2012-05-03
CA2804797C (en) 2014-12-23
EP3363439A3 (en) 2018-12-05
EP2632468B1 (en) 2017-12-13
US20130267506A1 (en) 2013-10-10
US10307428B2 (en) 2019-06-04
WO2012055018A1 (en) 2012-05-03
PL3363439T3 (pl) 2025-09-22
EP3363439A2 (en) 2018-08-22
RS66691B1 (sr) 2025-05-30
HUE070784T2 (hu) 2025-06-28
ES3016907T3 (en) 2025-05-12
CN103298473B (zh) 2015-07-29
EP3363439B1 (en) 2025-01-08
EP2632468A4 (en) 2014-08-27
EP2632468A1 (en) 2013-09-04
EP4537829A2 (en) 2025-04-16
PT2632468T (pt) 2018-03-02
NO2632468T3 (pl) 2018-05-12
EP3363439C0 (en) 2025-01-08
DK2632468T3 (en) 2018-02-12
US20240180922A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
IL245326B (en) pharmaceutical preparation
LT2619182T (lt) Farmacinė kompozicija
PL2616076T3 (pl) Kompozycje farmaceutyczne
IL225457A0 (en) Pharmaceutical composition
ZA201304189B (en) Novel pharmaceutical composition
EP2566487A4 (en) OPHTHALMIC COMPOSITION
PT2579858E (pt) Composição farmacêutica que contém ivabradina
ZA201301920B (en) Pharmaceutical composition
GB201010453D0 (en) Pharmaceutical composition
HUE051133T2 (hu) Gyógyászati készítmények
PT2632468T (pt) Composições terapêuticas para polineuropatia diabética simétrica
EP2560678A4 (en) PHARMACEUTICAL COMPOSITIONS
GB201001911D0 (en) Pharmaceutical composition
GB201019775D0 (en) Pharmaceutical composition
HU1000006D0 (en) Improved pharmaceutical composition
GB201008590D0 (en) Pharmaceutical compositions
PT2642996T (pt) Composições farmacêuticas